Mazandaran Association of Emergency Medicine Humanistic Studies and Social Researches 3092-6467 2 1 2025 12 22 The Efficacy of Cognitive Behavioral Therapy (CBT) in Treating Treatment-Resistant Depression 236911 10.22034/hssr.2025.236911 EN Mandana Javad Jaberi Department of Clinical Psychology, Islamic Azad University, Hamadan Branch, Hamadan, Iran Nafise Kianersi Department of Industrial-Organizational Psychology, Isfahan State University, Isfahan, Iran 0009-0005-7464-5199 Journal Article <strong><span style="font-size: 14.0pt; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: 'Times New Roman'; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi; color: #0f1115; mso-font-kerning: 0pt; mso-ligatures: none;">Background:</span></strong><span style="font-size: 14.0pt; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-fareast-font-family: 'Times New Roman'; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi; color: #0f1115; mso-font-kerning: 0pt; mso-ligatures: none;"> Treatment-resistant depression (TRD) represents a significant clinical challenge, associated with severe disability and high societal costs. Cognitive Behavioral Therapy (CBT) is a first-line psychotherapy, but its specific efficacy in TRD populations warrants detailed synthesis.<br><strong>Objective:</strong> This review aims to systematically evaluate the evidence for CBT as a monotherapy and augmentation strategy for TRD, examining its mechanisms, efficacy across delivery formats, predictors of response, and implementation challenges.<br><strong>Methods:</strong> A narrative review was conducted of randomized controlled trials, meta-analyses, and key observational studies published between 2000 and 2025. Literature was identified from PubMed, PsycINFO, and Cochrane Library databases and analyzed thematically.<br><strong>Results:</strong> Robust evidence supports CBT as an effective intervention for TRD. As an augmentation to pharmacotherapy, CBT significantly improves symptom reduction and remission rates compared to medication management alone. Specialized protocols, such as the Cognitive Behavioral Analysis System of Psychotherapy (CBASP), show particular promise for chronic presentations. Proposed mechanisms include the modification of persistent negative cognitive schemas and increased behavioral activation. Modest evidence suggests factors like cognitive flexibility and specific neuroimaging profiles may predict favorable outcomes.<br><strong>Conclusion:</strong> CBT is a validated and essential component of the TRD treatment arsenal. It addresses residual cognitive-behavioral symptoms often untouched by pharmacotherapy and provides durable, relapse-protective benefits. Future research must prioritize standardized TRD definitions, biomarker-driven personalization, and the optimization of scalable delivery models to improve accessibility and integration into stepped-care algorithms.</span> https://www.hssres.com/article_236911_f0471e2849791dd5107d850e0af083b8.pdf